PMID: 9189062May 1, 1997Paper

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2)

British Journal of Rheumatology
M J ElliottR N Maini

Abstract

Juvenile chronic arthritis (JCA) is the commonest chronic rheumatic disorder of childhood. Although conventional therapy of JCA continues to improve, many patients experience long-term ill health as a result of their disease or treatment. In adult rheumatoid arthritis (RA), similar concerns have led to the development of therapies designed to interfere in key disease processes. One such therapy is cA2, a chimeric neutralizing monoclonal antibody to the inflammatory cytokine, tumour necrosis factor-alpha (TNF-alpha). The administration of cA2 in adult RA has led to impressive short-term suppression of disease, with a good safety profile. Here, we report the first use of cA2 in childhood arthritis, choosing a patient with severe systemic-onset JCA, resistant to conventional therapies. The patient received two i.v. infusions of cA2, each at a dose of 10 mg/kg, separated by 1 week. The treatment was well tolerated and induced rapid control of fever, anorexia and serositis, together with downregulation of interleukin (IL)-6, soluble TNF receptors (sTNFR) and IL-1ra, and the acute-phase proteins C-reactive protein (CRP) and serum amyloid A (SAA). In contrast, we saw no significant improvement in joint pain or tenderness. Our findings...Continue Reading

Citations

Mar 28, 1998·The Journal of Experimental Medicine·T AlonziG Ciliberto
Mar 17, 2004·Annals of the Rheumatic Diseases·R J WakefieldP Emery
Apr 25, 2000·Annual Review of Medicine·R N Maini, P C Taylor
Sep 21, 2001·Current Rheumatology Reports·A M Prieur, G Chèdeville
Jan 9, 2003·Expert Opinion on Investigational Drugs·Lucila M A AgleThomas J A Lehman
Jan 16, 1999·Baillière's Clinical Rheumatology·R Schneider, R M Laxer
Feb 12, 2004·Pediatric Dermatology·M Alan Menter, John M Cush
Sep 25, 2004·Progress in Retinal and Eye Research·Andrew D DickAndrew P Cope
Jun 24, 2004·Expert Opinion on Pharmacotherapy·Andreas Otto Reiff
Apr 24, 2012·Molecular and Cellular Neurosciences·G N CostaP F Santos
Jan 11, 2001·The American Journal of Gastroenterology·R D CohenS B Hanauer
Jan 22, 2000·Arthritis and Rheumatism·X DongW H Reeves
Oct 18, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·J Eugene Huffstutter, Charles W Sienknecht
Jul 13, 2002·Arthritis and Rheumatism·M Elaine HusniMichael E Weinblatt
Aug 12, 2005·Current Opinion in Rheumatology·Alexa Adams, Thomas J A Lehman
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A M Prieur, P Quartier
May 8, 2002·Paediatric Drugs·Ian C Chikanza
May 15, 2013·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Juan Pablo VinickiHugo A Laborde
Oct 14, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·A SternL Buckley
Oct 14, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·P J WeisK D Pischel
Apr 17, 2001·The Annals of Pharmacotherapy·C J JohnsonK M Murray
Jul 26, 2002·The Cochrane Database of Systematic Reviews·B BlumenauerP Tugwell
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·F De Benedetti, A Ravelli
Feb 14, 2017·Canadian Journal of Gastroenterology & Hepatology·Flaminia CavallaroLuca Pastorelli
Oct 17, 2002·Rheumatic Diseases Clinics of North America·Diana S Milojevic, Norman T Ilowite

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.